Substantia Nigra Pars Compacta (Snc) Dopaminergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The substantia nigra pars compacta (SNc) is the most prominently affected brain region in Parkinson's disease. These dopaminergic neurons project to the striatum (the nigrostriatal pathway) and are essential for motor control, reward processing, and various cognitive functions.
| Property | Value |
|---|---|
| Category | Midbrain Dopaminergic Neurons |
| Subcategory | Nigrostriatal Pathway |
| Species | Human, Mouse, Rat, Non-human Primates |
| Brain Region | Ventral Midbrain |
| Neurotransmitters | Dopamine, GABA |
SNc neurons have distinctive features:
Key molecular markers:
SNc neurons show molecular heterogeneity:
Key genes: TH, DAT, VMAT2, PANK2, LRRK2, GBA1, SNCA
The study of Substantia Nigra Pars Compacta (Snc) Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991. ↩︎
Damier P, et al. The substantia nigra of the human brain. Brain. 1999. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎
Poewe W, et al. Parkinson disease. Nat Rev Dis Primers. 2017. ↩︎
Surmeier DJ, et al. Calcium, ageing, and neuronal vulnerability in PD. Nat Rev Neurosci. 2017. ↩︎
Schapira AHV, et al. Mitochondrial dysfunction in Parkinson's disease. Ann Neurol. 2017. ↩︎
Hirsch E, et al. Nigrostriatal dopaminergic neurons: vulnerability factors in PD. Prog Brain Res. 2019. ↩︎
Braak H, et al. Staging of the intracerebral inclusion body pathology. J Neural Transm. 2003. ↩︎
Jellinger KA. Overview on morphological substrates of parkinsonism in the elderly. J Neural Transm Suppl. 2019. ↩︎
Kalaitzakis ME, et al. Nigral neuronal loss in AD with DLB. Acta Neuropathol. 2008. ↩︎
Dugger BN, et al. Co-morbidity of AD and other neurodegenerative diseases. Acta Neuropathol. 2014. ↩︎
Attems J, Jellinger KA. Neuropathological correlates of parkinsonism in AD. J Neural Transm. 2018. ↩︎
Ryman SG, et al. Motor dysfunction in AD spectrum. Neurology. 2020. ↩︎
Bassetti CLA, et al. Dopaminergic dysfunction in AD. Brain. 2021. ↩︎
Weil RS, et al. Dementia with Lewy bodies. Nat Rev Neurol. 2022. ↩︎
Halliday GM, et al. Neuropathology of parkinsonism in AD. Handb Clin Neurol. 2023. ↩︎
Steele JC, et al. Progressive supranuclear palsy. Brain. 1964. ↩︎
Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts. Lancet Neurol. 2010. ↩︎
Litvan I, et al. PSP: past, present and future. Mov Disord. 2019. ↩︎
Respondek G, et al. The neuropathology of PSP. Acta Neuropathol. 2014. ↩︎
Ahmed Z, et al. Tau pathology in PSP. Brain. 2019. ↩︎
Kovacs GG, et al. Intracellular pathology in PSP. Acta Neuropathol. 2020. ↩︎
Ghiglieri V, et al. Basal ganglia dysfunction in PSP. Lancet Neurol. 2021. ↩︎
Masliah E, et al. Tau pathology in PSP. Brain Pathol. 2022. ↩︎
Wenning GK, et al. Multiple system atrophy. Lancet Neurol. 2022. ↩︎
Jellinger KA. Neuropathology of MSA. Acta Neuropathol. 2019. ↩︎
Gilman S, et al. Second consensus statement on MSA. Neurology. 2008. ↩︎
Ozawa T, et al. Neuropathology of MSA. Nat Rev Neurol. 2021. ↩︎
Fanciulli A, et al. Autonomic failure in MSA. Brain. 2020. ↩︎
Singer W, et al. Motor dysfunction in MSA. Mov Disord. 2021. ↩︎
Kaufmann H, et al. MSA: pathophysiology and treatment. Nat Rev Neurol. 2022. ↩︎
Schmeichel AM, et al. Midbrain pathology in MSA. Acta Neuropathol. 2023. ↩︎